While Ultragenyx provides financial support for this program, healthcare professionals must confirm that patients meet certain criteria to use the program and shall not seek reimbursement for the testing or services provided under this program from any third party, including but not limited to federal healthcare programs. Ultragenyx receives de-identified/anonymized data from this program, but at no time does Ultragenyx receive patient-identifiable information. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Ultragenyx product.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Clarke, L., Ellaway, C., Foster, H. C., Giugliani, R., Goizet, C., Goring, S., . . . Wijburg, F. (2018). Understanding the Early Presentation of Mucopolysaccharidoses Disorders: Results of a Systematic Literature Review and Physician Survey. Journal of Inborn Errors of Metabolism, 6, 1-12. doi:10.1177/2326409818800346
Gimovsky, A. C., Luzi, P., & Berghella, V. (2015, March). Lysosomal storage disease as an etiology of nonimmune hydrops. American Journal of Obstetrics and Gynecology, 212(3), 281-290. doi:10.1016/j.ajog.2014.10.007
Khan, S. A., Peracha, H., Ballhausen, D., Wiesbauer, A., Rohrbach, M., Gautschi, M., . . . Tomatsu, S. (2017). Epidemiology of mucopolysaccharidoses. Molecular Genetics and Metabolism, 121, 227-240. doi:10.1016/j.ymgme.2017.05.016
Lehman, T. J., Miller, N., Norquist , B., Underhill, L., & Keutzer, J. (2011, Dec). Diagnosis of the mucopolysaccharidoses. Rheumatology supplement, 50(Suppl_5), v41-v48. doi:10.1093/rheumatology/ker390
Montaño , A. M., Lock-Hock, N., Steiner, R. D., Graham, B. H., Szlago, M., Greenstein, R., . . . Sly, W. S. (2016, June). Clinical course of sly syndrome (mucopolysaccharidosis type VII). Journal of Medical Genetics, 53(6), 403-418. doi:10.1136/jmedgenet-2015-103322
Neufeld, E. F., & Muenzer, J. (2014). “The Mucopolysaccharidoses.” The Online Metabolic and Molecular Bases of Inherited Disease. (D. Valle, A. L. Beaudet, B. Vogelstein, K. W. Kinzler, S. E. Antonarakis , A. Ballabio, . . . G. Mitchell, Eds.) New York, NY: McGraw Hill. Retrieved from https://ommbid.mhmedical.com/content.aspx?bookid=971§ionid=62642135
Tomatsu, S., Fujii, T., Fukushi, M., Oguma, T., Shimada, T., Maeda, M., . . . Orii, T. (2013, Sep-Oct). Newborn screening and diagnosis of mucopolysaccharidoses. 110(1-2), 42-53. doi:10.1016/j.ymgme.2013.06.007
Vianey-Saban, C., Acquaviva, C., Cheillan, D., Collardeau-Frachon, S., Guibaud, L., Pagan, C., . . . Froissart, R. (2016, July 8). Antenatal manifestations of inborn errors of metabolism: biological diagnosis. Journal of Inherited Metabolic Disorders, 39, 611–624. doi:https://doi.org/10.1007/s10545-016-9947-8|